All In Biotech

Free tool

FAERS Monitor: Tiglutik Kit

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209080 or its brand name (Tiglutik Kit, Riluzole). Reports on generic versions are filed under their own applications.

Reports

2,216

Serious

1,375

62% of reports

Hospitalization

526

Death reported

521

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death319
  • nausea155
  • diarrhoea138
  • drug ineffective100
  • disease progression96
  • amyotrophic lateral sclerosis92
  • fatigue92
  • dyspnoea89
  • asthenia82
  • dizziness79
  • muscular weakness71
  • abdominal discomfort68
  • off label use64
  • headache59
  • pneumonia52

Reports by year received

View as table
YearReports
20046
200515
20067
200710
20089
20096
201013
201111
201215
201327
201421
201535
201639
201798
2018134
2019207
2020264
2021194
2022179
2023310
2024239
2025209
2026168

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,943 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
amyotrophic lateral sclerosisSignal92423.4345.136,719
disease progressionSignal967.76.3556
muscular weaknessSignal715.94.7288
abdominal discomfortSignal683.83.0142
deathSignal3193.53.2596
astheniaSignal822.11.745
diarrhoeaSignal1382.01.773
nausea1551.91.663
pneumonia521.51.29
dizziness791.51.213
dyspnoea891.51.214
fatigue921.10.91
headache590.90.71
drug ineffective1000.70.611
off label use640.70.59

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.